Search Results - "J. Li-Yu"

Predicting In Vivo Efficacy from In Vitro Data: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer by Bouhaddou, Mehdi, Yu, Li J., Lunardi, Serena, Stamatelos, Spyros K., Mack, Fiona, Gallo, James M., Birtwistle, Marc R., Walz, Antje‐Christine

“…Reliably predicting in vivo efficacy from in vitro data would facilitate drug development by reducing animal usage and guiding drug dosing in human clinical…”
Get full text

Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse by Jin, Ming, Casper, T. Charles, Cataland, Spero R., Kennedy, Melanie S., Lin, Shili, Li, Yu J., Wu, Haifeng M.

“…Summary Idiopathic thrombotic thrombocytopenic purpura (TTP) is characterized by frequent recurrences. Effective screening for relapses will enable…”
Get full text

Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? by J Li-Yu, G Clayburne, M Sieck, A Beutler, M Rull, E Eisner, H R Schumacher, Jr

“…OBJECTIVE: To determine if lowering of serum uric acid (SUA) concentrations below 6 mg/dl or longer duration of lowered SUA will result in depletion of urate…”
Get full text

Differences in N-glycan structures found on recombinant IgA1 and IgA2 produced in murine myeloma and CHO cell lines by Yoo, Esther M., Yu, Li J., Wims, Letitia A., Goldberg, David, Morrison, Sherie L.

“…The development and production of recombinant monoclonal antibodies is well established. Although most of these are IgGs, there is also great interest in…”
Get full text

Physiologically Based Absorption Modeling to Explore the Impact of Food and Gastric pH Changes on the Pharmacokinetics of Alectinib by Parrott, Neil J, Yu, Li J, Takano, Ryusuke, Nakamura, Mikiko, Morcos, Peter N.

“…Alectinib, a lipophilic, basic, anaplastic lymphoma kinase (ALK) inhibitor with very low aqueous solubility, has received Food and Drug…”
Get full text

Impact of Intracranial Artery Disease and Prior Cerebral Infarction on Central Nervous System Complications After Off-Pump Coronary Artery Bypass Grafting by Bi, Q., Li, J.-Yu, Li, X.-Q., Li, Q., Luo, D., Qiao, Q.-B.

“…We tried to determine whether postoperative CNS complications after off-pump coronary artery bypass grafting (OPCABG) are related to prior cerebral infarction…”
Get full text

The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents by DeNinno, Michael P., Andrews, Melissa, Bell, Andrew S., Chen, Yue, Eller-Zarbo, Cynthia, Eshelby, Nan, Etienne, John B., Moore, Dianna E., Palmer, Michael J., Visser, Michael S., Yu, Li J., Zavadoski, William J., Michael Gibbs, E.

“…Starting from the non-selective lead 1, the sequential use of library and directed synthesis led to the optimized PDE9 inhibitor 13. Starting from a…”
Get full text

Establishment of correlation between in vitro enzyme binding potency and in vivo pharmacological activity: application to liver glycogen phosphorylase a inhibitors by Yu, Li J, Chen, Yue, Treadway, Judith L, McPherson, R Kirk, McCoid, Scott C, Gibbs, E Michael, Hoover, Dennis J

“…In drug discovery, establishing a correlation between in vitro potency and in vivo activity is critical for the validation of the selected target and for…”
Get more information

SAP regulates T cell-mediated help for humoral immunity by a mechanism distinct from cytokine regulation by Cannons, Jennifer L, Yu, Li J, Jankovic, Dragana, Crotty, Shane, Horai, Reiko, Kirby, Martha, Anderson, Stacie, Cheever, Allen W, Sher, Alan, Schwartzberg, Pamela L

“…X-linked lymphoproliferative disease is caused by mutations affecting SH2D1A/SAP, an adaptor that recruits Fyn to signal lymphocyte activation molecule…”
Get full text

A survey on osteoporosis management among Filipino general practitioners by E. Veñegas, J. Li-Yu

Get full text

Investigating the effect of autoinduction in cynomolgus monkeys of a novel anticancer MDM2 antagonist, idasanutlin, and relevance to humans by Glenn, Kelli J., Yu, Li J., Reddy, Micaela B., Fretland, Adrian J., Parrott, Neil, Hussain, Sazzad, Palacios, Mary, Vazvaei, Faye, Zhi, Jianguo, Tuerck, Dietrich

“…1. Idasanutlin (RG7388) is a potent p53-MDM2 antagonist currently in clinical development for treatment of cancer. The purpose of the present studies was to…”
Get full text

Cysteine Residues Required for the Attachment of the Light Chain in Human IgA2 by Chintalacharuvu, Koteswara R, Yu, Li J, Bhola, Nishant, Kobayashi, Kunihiko, Fernandez, Christine Z, Morrison, Sherie L

“…In humans, there are two subclasses of IgA, IgA1 and IgA2, with IgA2 existing as three allotypes, IgA2m(1), IgA2m(2) and IgA2(n). In IgA1, Cys(133) in C(H)1…”
Get full text

Development of a Substrate-Activity Based Approach To Identify the Major Human Liver P-450 Catalysts of Cyclophosphamide and Ifosfamide Activation Based on cDNA-Expressed Activities and Liver Microsomal P-450 Profiles by Roy, P, Yu, L J, Crespi, C L, Waxman, D J

“…The contributions of specific human liver cytochrome P-450 (CYP) enzymes to the activation, via 4-hydroxylation, of the oxazaphosphorine anticancer prodrugs…”
Get full text

Erratum to: A 10-year follow up of postmenopausal women with osteoporosis for occurrence of osteoporotic fractures by Sunarso, S., Ngo, J., Li-Yu, J.

Get full text

Uniformity of ionization response of structurally diverse analytes using a chip-based nanoelectrospray ionization source by Hop, Cornelis E. C. A., Chen, Yue, Yu, Li J.

“…The major drawback of liquid chromatography/mass spectrometry (LC/MS) for the analysis of mixtures is the non‐quantitative nature of these studies. The…”
Get full text

Cardioprotective effects of ingliforib, a novel glycogen phosphorylase inhibitor by Tracey, W Ross, Treadway, Judith L, Magee, William P, Sutt, Jill C, McPherson, R Kirk, Levy, Carolyn B, Wilder, Donald E, Yu, Li J, Chen, Yue, Shanker, Ravi M, Mutchler, Alison K, Smith, Andrew H, Flynn, David M, Knight, Delvin R

“…Interventions such as glycogen depletion, which limit myocardial anaerobic glycolysis and the associated proton production, can reduce myocardial ischemic…”
Get more information

In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity by Yu, L J, Drewes, P, Gustafsson, K, Brain, E G, Hecht, J E, Waxman, D J

“…The widely used anticancer prodrug cyclophosphamide (CPA) is activated in liver by a 4-hydroxylation reaction primarily catalyzed by cytochrome P-4502B and…”
Get more information

Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene by CHEN, L, YU, L. J, WAXMAN, D. J

“…Intratumoral expression of cytochrome P450 2B1 sensitizes tumor cells to the cytotoxic action of the alkylating agent prodrug cyclophosphamide (CPA) and…”
Get full text

Investigation of the Relationship between Type 2 Diabetes and Osteoporosis Using Bayesian Inference by Sta Romana, M, Li-Yu, J T

“…Abstract This study aims to determine the prevalence of Type 2 diabetes in women with osteoporosis and estimate the odds ratio (OR) of osteoporosis in women…”
Get full text

Identification of a novel glutathione adduct of diclofenac, 4'-hydroxy-2'-glutathion-deschloro-diclofenac, upon incubation with human liver microsomes by YU, Li J, YUE CHEN, DENINNO, Michael P, O'CONNELL, Thomas N, HOP, Cornelis E. C. A

“…Clinical use of the nonsteroidal anti-inflammatory drug diclofenac (DF) is associated with an incidence of idiosyncratic hepatoxicity. The formation of…”
Get full text